Androgen receptors beyond prostate cancer: an old marker as a new target

Javier Munoz _, Jennifer J. Wheler and Razelle Kurzrock

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:592-603. https://doi.org/10.18632/oncotarget.2831

Metrics: PDF 2111 views  |   HTML 3037 views  |   ?  


Javier Munoz1,*, Jennifer J. Wheler2,* and Razelle Kurzrock3

1 Hematology-Oncology, Banner MD Anderson Cancer Center, Gilbert, Arizona

2 Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas

3 Center for Personalized Cancer Therapy, Division and Hematology and Oncology, Moores Cancer Center, The University of California San Diego, La Jolla, California

* These authors share first authorship


Jennifer J. Wheler, email:

Keywords: androgen receptor, therapy, molecular abnormalities, phase I clinical trials

Received: October 16, 2014 Accepted: November 14, 2014 Published: November 15, 2014


Androgen receptors (ARs) play a critical role in the development of prostate cancer. Targeting ARs results in important salutary effects in this malignancy. Despite mounting evidence that ARs also participate in the pathogenesis and/or progression of diverse tumors, exploring the impact of hormonal manipulation of these receptors has not been widely pursued beyond prostate cancer. This review describes patterns of AR expression in a spectrum of cancers, and the potential to exploit this knowledge in the clinical therapeutic setting.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 2831